|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Agenix Ltd., of Brisbane, Australia, signed a contract with Research Triangle Park, N.C.-based Diosynth Biotechnology to begin the process of manufacturing ThromboView for Phase III trials and commercial sales. Diosynth is expected to supply the product so Agenix can begin the pivotal trials by the third quarter of next year.
Biotech Holdings Ltd., of Vancouver, British Columbia, filed for a private placement of C$121,574 (US$100,000). The company will issue 419,220 shares at a price of C29 cents per share, with each share having a warrant exercisable at C38 cents for the purchase of an additional share. Proceeds from the investment will be used to continue the ...